Entry into the AAV gene therapy and rare neuromuscular disease businesses through the acquisition of Audentes Therapeutics

An individual M&A transaction to enter the gene therapy field by acquiring AAV-based gene therapy technology, manufacturing capabilities and a development pipeline for rare neuromuscular diseases through the acquisition of Audentes Therapeutics.